A Phase 1 interventional study of QLS1410 (CYP11B2 inhibitor) and placebo in Uncontrolled Hypertension, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-03.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 408 studies in Hypertension with a site in China — 123 open to participants now, 146 under way, 12 of them phase 3. Hypertension · China.
Among the 408 studies in Hypertension with a site in China, this one is the 242nd largest by planned enrollment of the 306 interventional ones that give a count, is one of 47 that started in 2025, is one of 19 in phase 1, reaches primary completion later than 39 of the 145 other live ones, and was the 347th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →123 of the 408 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–80
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China Medical University, China · Sites in China
Ages 50–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
408 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 23 · Phase 3 50 · Phase 4 76
First in 1998; this study’s year is marked. 47 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 255 across the 306 interventional studies, 1,000 across the 102 observational. Of the 161 that completed or were terminated, 22 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 408 have an industry lead sponsor. The 10 most frequent:
Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.
Qilu Pharmaceutical Co., Ltd. has 4 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
45 of the studies in Hypertension with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
Add all 45 to your calendar (.ics) → With an account.
Among the 408 studies in Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of single and multiple ascending doses of QLS1410 in healthy Chinese adults and participants with mild essential hypertension
This study consists of three parts, as follows:
Part A is a randomized, placebo-controlled, double-blind single ascending dose (SAD) study in healthy Chinese adults, consisting of 5 cohorts. Starting dose of 0.5 mg by oral administration are planned. Once sufficient safety and PK data are obtained from the SAD cohorts, the SMC will determine the dosage of initial cohort in Part B and Part C.
Part B is a randomized, open-label, two-cycle, crossover food effect (FE) study under fasting and fed (high-fat meal) conditions.
Part C is a randomized, placebo-controlled, double-blind multiple ascending doses (MAD) study in participants with mild essential hypertension, consisting of 3 cohorts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Part C: Participants with Mild Essential Hypertension
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Healthy adults will be randomized (6:2) to receive a single dose (1.5 mg \~ 20 mg) of QLS1410 or placebo,especially, the starting dose will be 0.5 mg of QLs1410 Part B: QLS1410 will be administered under the fasted or fed conditions in two different periods separated by a wash-out interval of 14 days. The dose of QLS1410 or placebo is based on upcoming data from SAD part. Part C: Hypertensive participants will be randomized (8:2) to receive QLS1410 or placebo QD for 14 continuous days. The starting dose of QLS1410 or placebo is based on upcoming data from SAD part.
Drug: QLS1410 (CYP11B2 inhibitor)
Part A: Healthy adults will be randomized (6:2) to receive a single dose (1.5 mg \~ 20 mg) of QLS1410 or placebo Part B: QLS1410 will be administered under the fasted or fed conditions in two different periods separated by a wash-out interval of 14 days. The dose of QLS1410 or placebo is based on upcoming data from SAD part. Part C: Hypertensive participants will be randomized (8:2) to receive QLS1410 or placebo QD for 14 continuous days. The starting dose of QLS1410 or placebo is based on upcoming data from SAD part.
Drug: placebo
QLS1410 tablets
Matching placebo tablets
Incidence and severity of treatment emergent Adverse Events as assessed by CTCAE v5.0
Time frame: up to approximately 1 month
Area under the curve plasma concentration from time zero to last measurable concentration [AUC(0-last)]
Time frame: up to approximately 1 month
Area under the curve plasma concentration from time zero to infinity [AUC(0-∞)]
Time frame: up to approximately 1 month
Maximum observed plasma concentration (Cmax)
Time frame: up to approximately 1 month
Terminal elimination half-life (t1/2)
Time frame: up to approximately 1 month
Apparent clearance (CL/F)
Time frame: up to approximately 1 month
Apparent volume of distribution (Vz/F)
Time frame: up to approximately 1 month
Mean residence time (MRT)
Time frame: up to approximately 1 month
Start is estimated for Sep 2025; primary completion for May 2026, 8 months later.
Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 8 months is above that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: QLS1410
Qilu Pharmaceutical Co., Ltd. →